As clinical and dermatological research continues to evolve, 3D reconstructed tissue models, such as reconstructed human epidermis (RHE) and mucosal epithelium, are reshaping the way efficacy and safety are evaluated. These advanced in vitro systems closely replicate human biology, offering reliable, reproducible and ethically preferable alternatives to animal testing. Their applications span from irritation and corrosion testing to drug absorption and disease modeling. However, the full value of these models depends on rigorous validation and a clear understanding of their scope and limitations.
This white paper examines the expanding role of 3D skin and epithelial models, the shift toward human-relevant and non-animal approaches and how standardized protocols can support confident, science-driven decisions in product development and regulatory pathways.
